Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

doi:10.4251/wjgo.v15.i10.1771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2938)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1654

Figures (1-4)

221

Tables (1-5)

209

Sum=2182

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

144

Download

493

Sum=637

Oct 15, 2023 (publication date) through Jan 4, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1771-1783
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1771

Table 4 Treatment after progression on atezolizumab plus bevacizumab therapy¹, n (%)

Treatment	Total, n = 37	mALBI 1 + 2a, n = 24	mALBI 2b + 3, n = 13	P value
Systemic therapy	32 (86.5)	22 (91.7)	10 (76.9)	0.320
TACE	4 (10.8)	4 (16.7)	0 (0)	0.280
EBRT	8 (21.6)	6 (25.0)	2 (15.4)	0.690
Best supportive care	4 (10.8)	1 (4.2)	3 (23.1)	0.120

¹There were 37/83 (44.6%) patients who had disease progression after atezolizumab plus bevacizumab therapy. EBRT: External beam radiotherapy; mALBI: Modified albumin-bilirubin; TACE: Transarterial chemoembolization.

Citation: Navadurong H, Prasoppokakorn T, Siriwong N, Phathong C, Teeyapun N, Tanasanvimon S, Thanapirom K, Komolmit P, Tangkijvanich P, Treeprasertsuk S, Chaiteerakij R. Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy. World J Gastrointest Oncol 2023; 15(10): 1771-1783
URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1771.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i10.1771